Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with George Small, MD, an adult neurologist at Allegheny Health Network. [LISTEN TIME: minutes]
In the latest edition of our in-depth Q&A series, the codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.
The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke about the well-being of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]
Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Debra Davis, CRN, discuss the relationship between sleep disorders and other health conditions, such as cardiovascular, respiratory, and psychiatric diseases in this NeurologyLive® Peers & Perspectives series, called, "Advanced Practice Providers’ Perspectives on Sleep Disorders: Impact of Insomnia on Patient Health."